Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

Logo poskytovatele

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

KRYUKOV Fedor DEMENTYEVA Elena Vladimirovna KUBICZKOVÁ Lenka JARKOVSKÝ Jiří BROŽOVÁ Lucie PETRÍK Jakub NĚMEC Pavel ŠEVČÍKOVÁ Sabina MINARIK Jiri STEFANIKOVA Zdena KUGLÍK Petr HÁJEK Roman

Rok publikování 2013
Druh Článek v odborném periodiku
Časopis / Zdroj Genomics
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1016/j.ygeno.2013.06.007
Obor Onkologie a hematologie
Klíčová slova Multiple myeloma; Plasma cell leukemia; Cell cycle genes; Overall survival; Time-to-progression
Popis The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 +/- 3.9 months for 'low' expressed and 7.5 +/- 5.6 months for 'high' expressed group, p < 0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 +/- 3.6 months for 'low' and 8.4 +/- 2.7 months for 'high' expressed group, p < 0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 +/- 2.8 months for 'low' and 9.8 +/- 1.1 months for 'high' expressed group, p < 0.0001). The overexpression of inhibitors can be explained as a compensatory reaction to growing "oncogenic stress".
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.